Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington’s disease, viral conditions such as HIV, and cancers

Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington’s disease, viral conditions such as HIV, and cancers
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.
Learn about our programme of events and sign up to be alerted for future events
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim.
A portfolio of human colorectal adenocarcenoma cell lines including primary cell lines isolated from patients (of various Duke’s stages and histological grades) in addition to cloned cells lines genetically modified to highly express alpha integrin domains.
Proposed use Research into Charcot-Marie Tooth Disease (Type 1A). Research into autoimmune neurological disorders would be the main target market. Problem addressed Construction of models of human inherited diseases is particularly important for testing gene therapy...
A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.